Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer (vol 10, 3470, 2020)

被引：1
|
作者：
Moufarrij, Sara
Srivastava, Aneil
Gomez, Stephanie
Hadley, Melissa
Palmer, Erica
Austin, Paul Tran
Chisholm, Sarah
Diab, Noor
Roche, Kyle
Yu, Angela
Li, Jing
Zhu, Wenge
Lopez-Acevedo, Micael
Villagra, Alejandro
Chiappinelli, Katherine B.
机构：
[1] The George Washington University,The George Washington University Cancer Center
[2] The George Washington University,The Department of Obstetrics & Gynecology
[3] The George Washington University,The Department of Microbiology, Immunology, & Tropical Medicine
[4] The George Washington University,The Department of Biochemistry and Molecular Medicine
[5] The George Washington University,The Institute for Biomedical Sciences
来源：
SCIENTIFIC REPORTS | 2021年 / 11卷 / 01期
关键词：
D O I：
10.1038/s41598-021-04066-1
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：1
相关论文
共 28 条
  • [1] Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Sara Moufarrij
    Aneil Srivastava
    Stephanie Gomez
    Melissa Hadley
    Erica Palmer
    Paul Tran Austin
    Sarah Chisholm
    Noor Diab
    Kyle Roche
    Angela Yu
    Jing Li
    Wenge Zhu
    Micael Lopez-Acevedo
    Alejandro Villagra
    Katherine B. Chiappinelli
    Scientific Reports, 10
  • [2] Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Moufarrij, Sara
    Srivastava, Aneil
    Gomez, Stephanie
    Hadley, Melissa
    Palmer, Erica
    Austin, Paul Tran
    Chisholm, Sarah
    Roche, Kyle
    Yu, Angela
    Li, Jing
    Zhu, Wenge
    Lopez-Acevedo, Micael
    Villagra, Alejandro
    Chiappinelli, Katherine B.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [3] Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Sara Moufarrij
    Aneil Srivastava
    Stephanie Gomez
    Melissa Hadley
    Erica Palmer
    Paul Tran Austin
    Sarah Chisholm
    Noor Diab
    Kyle Roche
    Angela Yu
    Jing Li
    Wenge Zhu
    Micael Lopez-Acevedo
    Alejandro Villagra
    Katherine B. Chiappinelli
    Scientific Reports, 11
  • [4] HDAC6 and DNMT inhibition affect immunogenicity of ovarian cancer cells: A rationale for combining epigenetic and immune therapy in ovarian cancer
    Srivastava, Aneil P.
    Moufarrij, Sara M.
    Hadley, Melissa
    Chisholm, Sarah
    Lopez-Acevedo, Micael
    Villagra, Alejandro
    Chiappinelli, Katherine B.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer
    Kayla V. Myers Chen
    Amber E. de Groot
    Sabrina A. Mendez
    Mikaela M. Mallin
    Sarah R. Amend
    Kenneth J. Pienta
    Medical Oncology, 40
  • [6] Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer
    Chen, Kayla V. Myers
    de Groot, Amber E.
    Mendez, Sabrina A.
    Mallin, Mikaela M.
    Amend, Sarah R.
    Pienta, Kenneth J.
    MEDICAL ONCOLOGY, 2023, 40 (10)
  • [7] Selective HDAC6 inhibition by SP-2-225 enhances the innate anti-tumor immune response after radiation exposure
    Grindrod, Scott
    Noonepalle, Satish
    Li, Xingtang
    Quiceno, David
    Jung, Mira
    Dritschilo, Anatoly
    Villagra, Alejandro
    CANCER RESEARCH, 2024, 84 (01)
  • [8] HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
    Oba, Takaaki
    Ono, Mayu
    Matoba, Hisanori
    Uehara, Takeshi
    Hasegawa, Yoshie
    Ito, Ken-ichi
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (01) : 37 - 51
  • [9] HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
    Takaaki Oba
    Mayu Ono
    Hisanori Matoba
    Takeshi Uehara
    Yoshie Hasegawa
    Ken-ichi Ito
    Breast Cancer Research and Treatment, 2021, 186 : 37 - 51
  • [10] Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells
    Sodre, Andressa L.
    Woods, David M.
    Sarnaik, Amod
    Betts, Brian C.
    Quayle, Steven
    Jones, Simon
    Weber, Jeffrey
    CANCER RESEARCH, 2017, 77
123